Eli Lilly has initiated a Phase I study of an antibody-based drug, LY-CoV555, against Covid-19. This drug candidate was identified and developed as part of Lilly’s collaboration with Vancouver-based AbCellera signed in early May.
LY-CoV555 is an IgG1 monoclonal antibody, which targets the spike protein of SARS-CoV-2, the virus which causes Covid-19.
Go deeper with GlobalData
This randomised, placebo-controlled Phase I study aims to find out if LY-CoV555 is safe and tolerable in patients hospitalised with Covid-19. Results of this study are expected in late June, and then Lilly hopes it can quickly progress into a Phase II study of non-hospitalised Covid-19 patients.
Lilly chief scientific officer Daniel Skovronsky said: “We are privileged to help usher in this new era of drug development with the first potential new medicine specifically designed to attack the virus.
“Antibody therapies, such as LY-CoV555, may have potential for both prevention and treatment of COVID-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
